DPP4 and type 2 diabetes mellitus: Indeed, the most recent addition to the body of evidence is a population-based, retrospective cohort study of 255 691 South Korean patients with type 2 diabetes mellitus newly prescribed either DPP-4 inhibitors or sulfonylureas.